Evoke Pharma Inc.

AI Score

0

Unlock

4.26
0.03 (0.71%)
At close: Jan 14, 2025, 3:58 PM
4.31
1.17%
After-hours Jan 14, 2025, 03:59 PM EST
undefined%
Bid 4.08
Market Cap 6.33M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -10.13
PE Ratio (ttm) -0.42
Forward PE n/a
Analyst n/a
Ask 4.51
Volume 12,174
Avg. Volume (20D) 401,962
Open 4.17
Previous Close 4.23
Day's Range 4.17 - 4.49
52-Week Range 3.54 - 12.32
Beta undefined

About EVOK

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine ...

Sector Healthcare
IPO Date Sep 25, 2013
Employees 4
Stock Exchange NASDAQ
Ticker Symbol EVOK

Next Earnings Release

Evoke Pharma Inc. is scheduled to release its earnings on Mar 13, 2025, during market hours.
Analysts project revenue of $3.74M, reflecting a 123.15% YoY growth and earnings per share of -0.25, making a -96.47% decrease YoY.
3 weeks ago · Source
+24.77%
Evoke Pharma shares are trading higher after the c... Unlock content with Pro Subscription
2 months ago · Source
+33.58%
Evoke Pharma shares are trading higher after the company announced the presentation of GLP-1 data for users with diabetic gastoparesis using GIMOTI and showed statistically significant improvements.